“(D) In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term at the retail level refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation.” – Sec. 3 – subsection (c)(1)(D)
The Act amends the Controlled Substances Act to add more than 25 new substances to current lists of defined anabolic steroids, and revises the process whereby new substances can be added in future. It also calls for DEA to address products that are “substantially similar” to anabolic steroids and that have been illegally marketed to promote muscle growth. DASCA’s provisions include new DEA authority to place new anabolic steroids on the DEA Controlled Substance List and new criteria for placing additional anabolic steroids on the list going forward that will better enable DEA to identify and catalog new chemicals. DASCA will allow DEA to quickly crack down on criminals creating new anabolic substances that closely resemble red-flagged counterparts listed, but altered minimally with the intent of evading enforcement.